文献速递其他结缔组织病

自体干细胞移植治疗难治性幼年起病系统性硬化症

Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc).
PubMed 文献 · Ann Rheum Dis · 2026-06-17

该单中心研究报告8例对≥2种改善病情抗风湿药难治的中重度幼年起病系统性硬化症患者接受CD34+选择性自体干细胞移植的结果。中位随访30个月期间无事件生存率100%,无治疗相关死亡或器官毒性,皮肤评分中位改善93%,多系统功能及生活质量改善。结论认为ASCT安全耐受且带来持久多系统改善,支持对进行性难治性JSSc患者更早考虑ASCT。

要点

  • 8例难治性JSSc患者接受ASCT,无治疗相关死亡或器官毒性。
  • 中位随访30个月无事件生存率100%,皮肤评分中位改善93%。
  • 多数患者多系统功能改善,支持对进行性难治病例更早考虑ASCT。

核心结论

  • ASCT在难治性JSSc患者中安全且耐受良好,并带来持久的多系统改善。
  • 研究结果支持对具有进行性、治疗抵抗性疾病的JSSc患者更早考虑ASCT。

研究设计与样本

  • 单中心报告8例连续接受ASCT的治疗难治性JSSc患者。
  • 入组患者为中重度JSSc且对≥2种改善病情抗风湿药难治。
  • 采用CD34+选择性ASCT,方案经机构审查委员会和美国食品药品监督管理局批准(ClinicalTrials.gov: NCT03630211)。
  • 预处理包括阿仑单抗、利妥昔单抗、抗胸腺细胞球蛋白、全身照射和塞替派。
  • 在基线及ASCT后每6个月评估临床结局,直至48个月。

主要发现

  • 所有患者均成功植入,中性粒细胞和血小板植入中位时间分别为13天和22天。
  • 无治疗相关死亡或器官毒性。
  • 中位随访30个月时无事件生存率(无死亡、心肺衰竭或肾危象)为100%。
  • 改良Rodnan皮肤评分中位改善93%,6分钟步行距离改善13%。
  • 所有患者在ASCT后≥18个月停用免疫抑制,1例 later 因疾病复发需重新开始免疫抑制。

关键数值与推荐

  • 难治性定义:对≥2种改善病情抗风湿药难治。
  • 无事件生存定义为无死亡、心肺衰竭或肾危象。
  • 皮肤评分采用改良Rodnan皮肤评分,中位改善93%。
  • 6分钟步行距离改善13%。

临床怎么用

  • 对于中重度、对≥2种改善病情抗风湿药难治的JSSc患者,ASCT可作为治疗选择。
  • ASCT后多数患者可停用免疫抑制≥18个月,但需监测疾病复发。
  • ASCT后应定期评估皮肤、肺功能、肺动脉压力、胃肠道症状、肌肉骨骼功能及生活质量。

局限性

  • 单中心、小样本(8例)研究,随访时间有限(中位30个月)。
  • 无对照组,无法直接比较ASCT与其它治疗的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Juvenile-onset systemic sclerosis (JSSc) is a rare autoimmune disease characterised by vasculopathy and multiorgan fibrosis, leading to significant morbidity and early mortality. Autologous stem cell transplantation (ASCT) is an established therapy for severe adult systemic sclerosis, but data in JSSc are limited. We reported outcomes of 8 consecutive patients with treatment-refractory JSSc who received ASCT at a single centre. METHODS: Patients with moderate-to-severe JSSc refractory to ≥ 2 disease-modifying antirheumatic drugs underwent CD34+-selected ASCT using institutional review board- and US Food and Drug Administration-approved protocols (ClinicalTrials.gov: NCT03630211). Conditioning included alemtuzumab, rituximab, antithymocyte globulin, total body irradiation, and thiotepa. Clinical outcomes were assessed at baseline and every 6 months up to 48 months post-ASCT. RESULTS: All patients engrafted successfully (median neutrophil and platelet engraftment: 13 and 22 days, respectively). There were no treatment-related deaths or organ toxicities. Event-free survival (no death, cardiopulmonary failure, or renal crisis) was 100% at a median follow-up of 30 months. Skin scores (modified Rodnan skin score) improved by a median of 93%, and 6-minute walk distance improved by 13%. All patients discontinued immunosuppression for ≥18 months post-ASCT; 1 patient later required reinitiation for disease flare. Pulmonary function stabilised; both patients with pulmonary hypertension showed normalised pulmonary pressures. Gastrointestinal symptoms, including oesophageal motility and reflux, improved in most patients. Musculoskeletal function (Childhood Health Assessment Questionnaire and Childhood Myositis Assessment Scale), vascular symptoms, and quality of life (Scleroderma Health Assessment Questionnaire and performance scores) improved across the cohort. CONCLUSIONS: ASCT was safe and well-tolerated in patients with refractory JSSc and resulted in durable, multisystem improvement. These findings support earlier consideration of ASCT for patients with JSSc with progressive, treatment-resistant disease.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Torok KS, Horvei P, Li J, et al. Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc). Ann Rheum Dis. 2026. PMID: 42309868. doi:10.1016/j.ard.2026.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。